First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

The product, called Merilog, is the first fast-acting insulin biosimilar to get a federal nod. Biosimilars are near-identical versions of FDA-approved biologic drugs, offering the same safety and ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...

Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

Some people with diabetes use regular insulin because it costs less than rapid-acting insulin. This medication is available in pharmacies without a prescription, but you do need to ask the ...

Inhaled insulin is an “important alternative” to injected rapid-acting analog insulin for children and teens with diabetes, ...

The Food and Drug Administration (FDA) has approved Merilog ... The rapid-acting insulin should be administered subcutaneously within 5-10 minutes before a meal into the abdominal area, ...

Merilog also marks the third insulin biosimilar approved in the United States, following two long-acting biosimilars approved in 2021. 1 "The FDA has now approved three biosimilar insulin products to ...

New study results demonstrated the safety and efficacy of the MannKind Afrezza inhaled insulin offering for children with ...